Michael Cecchini, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Seattle Genetics
    Date added:
    07/16/2024
    Date updated:
    07/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Taiho
    Date added:
    07/16/2024
    Date updated:
    07/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Regeneron
    Date added:
    07/16/2024
    Date updated:
    07/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Incendia Therapeutics
    Date added:
    07/16/2024
    Date updated:
    07/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Agenus
    Date added:
    07/16/2024
    Date updated:
    07/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    LoxoLilly
    Date added:
    07/16/2024
    Date updated:
    07/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    AstraZeneca
    Date added:
    07/16/2024
    Date updated:
    07/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Daiichi Sankyo
    Date added:
    07/16/2024
    Date updated:
    07/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Beigene
    Date added:
    07/16/2024
    Date updated:
    07/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Arcus
    Date added:
    07/16/2024
    Date updated:
    07/16/2024
Return to 4th Binaytara Precision Oncology Summit: Current Standards and Emerging Therapies